Literature DB >> 25680347

[Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].

K Wand1, S Abraham2, D Loos2, S Stumpfe2, C Lohmann2, M Maier2, N Feucht2.   

Abstract

This article describes the case of a 22-year old female patient, who first presented with holocephalic headaches and bilateral loss in vision. After diagnosis of a complete Vogt-Koyanagi-Harada syndrome, high-dose corticosteroid therapy was initiated. Due to recurrent headaches 6 weeks later, immunosuppressive therapy was initiated with cyclosporine A. Because of an adverse effect (hirsutism) treatment was changed to azathioprine. In a long-term follow-up over 2 years the patient showed stable clinical findings with good visual acuity.

Entities:  

Keywords:  Azathioprine; Cyclosporine; Immunosuppressive agents; Uveitis; Visual acuity

Mesh:

Substances:

Year:  2015        PMID: 25680347     DOI: 10.1007/s00347-015-3238-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  9 in total

1.  Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.

Authors:  Russell W Read; Fei Yu; Massimo Accorinti; Bahram Bodaghi; Soon-Phaik Chee; Christine Fardeau; Hiroshi Goto; Gary N Holland; Hidetoshi Kawashima; Eri Kojima; Phuc Lehoang; Claire Lemaitre; Annabelle A Okada; Paola Pivetti-Pezzi; Antonio Secchi; Robert F See; Khalid F Tabbara; Masahiko Usui; Narsing A Rao
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

Review 2.  [Choroiditis].

Authors:  S Thurau; G Wildner
Journal:  Ophthalmologe       Date:  2010-01       Impact factor: 1.059

3.  Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease.

Authors:  Miguel Cuchacovich; Federica Solanes; Gonzalo Díaz; Tomás Cermenati; Samuel Avila; Juan Verdaguer; Juan Ignacio Verdaguer; Cristian Carpentier; Juan Stopel; Basilio Rojas; Leonidas Traipe; Patricia Gallardo; Francisca Sabugo; Mario Zanoli; Guillermo Merino; Francisco Villarroel
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

4.  Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.

Authors:  R W Read; G N Holland; N A Rao; K F Tabbara; S Ohno; L Arellanes-Garcia; P Pivetti-Pezzi; H H Tessler; M Usui
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

Review 5.  Vogt-Koyanagi-Harada disease: diagnosis and treatments update.

Authors:  Marcela F Bordaberry
Journal:  Curr Opin Ophthalmol       Date:  2010-11       Impact factor: 3.761

6.  The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease.

Authors:  Sang Jin Kim; Hyeong Gon Yu
Journal:  Ocul Immunol Inflamm       Date:  2007 Sep-Oct       Impact factor: 3.070

Review 7.  Vogt-Koyanagi-Harada syndrome.

Authors:  R S Moorthy; H Inomata; N A Rao
Journal:  Surv Ophthalmol       Date:  1995 Jan-Feb       Impact factor: 6.048

Review 8.  Vogt-koyanagi-harada syndrome.

Authors:  Wang Fang; Peizeng Yang
Journal:  Curr Eye Res       Date:  2008-07       Impact factor: 2.424

9.  Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease.

Authors:  Hossein Nazari; Narsing A Rao
Journal:  Br J Ophthalmol       Date:  2012-08-31       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.